Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. (7th January 2015) - Ou, Sai-Hong Ignatius
Abstract : This report describes a patient with ALK -rearranged non-small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only "site" of progression after a prolonged response to crizotinib and who has been treated successfully with a second-generation ALK inhibitor alone for >15 months.